What the Study Found (In Plain English)
Published in Malaria journal (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: Vector control is the most important malaria prevention strategy in Zambia. Key clinical takeaway: ATSB Sarabi v.1.2 as deployed in western Zambia were not likely to be cost -effective. ATSB would need to demonstrate higher or more certain efficacy along with affordable alternative distribution strategies prior to any deployment at scale.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Malaria journal, 2025-12-19; Phase III Randomized Trial; Rigor 82/100): ATSB Sarabi v.1.2 as deployed in western Zambia were not likely to be cost -effective. ATSB would need to demonstrate higher or more certain efficacy along with affordable alternative distribution strategies prior to any deployment at scale.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.